A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma

Potential synergistic interaction between gemcitabine (GEM) and epirubicin (EPI) in pancreatic cancer have been described previously. The maximum-tolerated dose in this trial was GEM 1000 mg m(−2) and EPI 45 mg m(−2). Median time to progression was 5.1 months and median survival time 7.4 months. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Eickhoff, A, Martin, W, Hartmann, D, Eickhoff, J C, Möhler, M, Galle, P R, Riemann, J F, Jakobs, R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361302/
https://www.ncbi.nlm.nih.gov/pubmed/16721369
http://dx.doi.org/10.1038/sj.bjc.6603174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361302/
https://www.ncbi.nlm.nih.gov/pubmed/16721369
http://dx.doi.org/10.1038/sj.bjc.6603174

Ejemplares similares